/nginx/o/2020/12/09/13520915t1h2c3f.jpg?fit=%2C&ssl=1 "UK warns people with severe allergies not to get vaccinated with Pfizer and BioNTech Covid-19 – Abroad – News")
Officials issued the warning after two British National Health Service staff, one of the first to receive the new vaccine on Tuesday, suffered an allergic reaction and needed medical attention.
–
Both workers, who have had allergies in the past, are now recovering.
–
Following the incident, the independent Medicines and Healthcare Products Regulatory Agency (MHRA) has advised people with a history of significant allergic reactions not to be vaccinated with the Covid-19 vaccine developed by Pfizer and BioNTech as a precaution.
–
According to the MHRA, a significant allergic reaction includes allergies to medications, vaccines, and food.
–
It has already been reported that the British National Health Service on Tuesday launched a program to vaccinate the population against the new coronavirus.
–
Several thousand people have already been vaccinated.
–
The vaccine should be stored at minus 70 degrees Celsius and vaccination of one person requires two doses given 21 days apart.
–
In the UK, hospital patients over the age of 80 were vaccinated first, as well as British National Health Service staff who will carry out the vaccination, and other UK National Health Service staff at high risk of infection.
–
The UK has already provided 800,000 doses of the vaccine and ordered a total of 40 million doses, enough to vaccinate 20 million people.
–
Most doses of the vaccine will not be available to humans until next year, although government sources have reported that four million more doses will be delivered to Britain by the end of the year.
–
Albert Burla, head of Pfizer, said on Tuesday that he understood global concerns about the development of the Covid-19 vaccine in such a short time and stressed that all concerns had been taken into account.
–
The Covid-19 vaccine has been tested in exactly the same way as other vaccines, Burla said.
–
Pfizer reported that it had been informed of the allergic reaction by the MHRA, but noted that in the third phase of the trial, which involved more than 40,000 people, the vaccine was generally well tolerated and did not raise serious safety concerns.
— .
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/GJUSEUD3M2M2CDA56FLVV2RAEA.jpg?resize=150%2C150&ssl=1 "British authorities call for Pfizer vaccine to be avoided in patients with severe allergic history | Society")
